Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $25.20 USD
Change Today 0.00 / 0.00%
Volume 20.9K
TRNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:50 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

tornier nv (TRNX) Snapshot

Open
$25.14
Previous Close
$25.20
Day High
$25.61
Day Low
$25.14
52 Week High
10/31/14 - $28.53
52 Week Low
05/5/14 - $17.51
Market Cap
1.2B
Average Volume 10 Days
106.0K
EPS TTM
$-0.48
Shares Outstanding
49.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TORNIER NV (TRNX)

tornier nv (TRNX) Related Businessweek News

No Related Businessweek News Found

tornier nv (TRNX) Details

Tornier N.V., a medical device company, designs, manufactures, markets, and sells orthopaedic products in the United States, France, and internationally. It offers joint implants and bone fixation devices for the shoulder, hand, wrist, elbow, foot, and ankle; sports medicine and biologics products that is used to mechanically repair tissue-to-tissue or tissue-to-bone injuries; and hip and knee joint replacement implants and other ancillary products, including instrumentation. It principally serves surgeons who treat musculoskeletal injuries; and disorders of the shoulder, elbow, hand, wrist, ankle, and foot. The company markets and sells its products through direct sales representatives and independent sales agencies in the United States; and direct sales offices and distributors in approximately 40 countries. Tornier N.V. is headquartered in Amsterdam, the Netherlands.

1,121 Employees
Last Reported Date: 02/24/15

tornier nv (TRNX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $548.6K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $364.4K
Senior Vice President of U.S. Commercial Oper...
Total Annual Compensation: $368.7K
Senior Vice President of International Commer...
Total Annual Compensation: $366.3K
Chief Legal Officer, Senior Vice President an...
Total Annual Compensation: $330.0K
Compensation as of Fiscal Year 2014.

tornier nv (TRNX) Key Developments

Tornier N.V. and Enter into Incremental Term Facility Amendment Agreement

On March 13, 2015, Tornier N.V. and Tornier, Inc. entered into an Incremental Term Facility Amendment with Bank of America, N.A., as Administrative Agent and other lenders party thereto. The Amendment amends that certain Credit Agreement, dated as of October 4, 2012, among Tornier, the Borrower, the Administrative Agent and the other lenders party to such Credit Agreement, and as previously amended by the First Amendment dated as of May 6, 2013 to the Credit Agreement. The subsidiaries of Tornier that are Guarantors under the Credit Agreement and also are parties to the Amendment are Tornier US Holdings, Inc., OrthoHelix Surgical Designs, Inc., Tornier UK Limited, Tornier Orthopedics Ireland Limited and Tornier SAS. Under the terms of the Amendment, the senior secured term loan facility denominated in U.S. dollars available to the Borrower under the Credit Agreement was increased by an additional aggregate principal amount of USD 10 million and the amortization schedule of such senior secured term loan facility to the Borrower denominated in U.S. dollars was revised to reflect the Additional USD Term Loan Advance. The proceeds of the Additional USD Term Loan Advance will be used to pay the fees and costs of the Amendment and for general corporate purposes.

Tornier Announces U.S. FDA Clearance of Simpliciti(TM) Shoulder System

Tornier N.V. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market the Simpliciti™ Shoulder System, which is a unique, bone sparing total shoulder arthroplasty system designed to treat patients experiencing severe shoulder joint pain, compromised range of motion, loss of strength and functionality. This novel, first to market system in the United States provides surgeons with an efficient, repeatable surgical technique that is intended to preserve both the patient's native bone and avoid further trauma to the surrounding soft tissue. Designed in partnership with shoulder surgeons to address the challenges associated with implantation of conventional, long stemmed prostheses, Simpliciti provides upper extremity surgeons with an innovative humeral component, which is intended to deliver the freedoms of precise anatomic placement without the constraints of fixed inclinations, medial offset or posterior offset. Simpliciti is intended to uniquely deliver anatomic results without the procedural complexity of traditional stemmed components. Designed to minimize bone removal and soft tissue disruption, the Simpliciti Shoulder System provides surgeons with an earlier intervention option for treatment of younger patients with shoulder osteoarthritis.

Tornier N.V. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year Ending December 27, 2015

Tornier N.V. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, revenue was $92.403 million against $83.392 million a year ago. Operating loss was $4.013 million against $7.340 million a year ago. Loss before income taxes was $6.459 million against $7.340 million a year ago. Consolidated net loss was $8.465 million or $0.17 per basic and diluted share against $10.699 million or $0.22 per basic and diluted share a year ago. Net cash provided by operating activities was $5.525 million against $6.661 million a year ago. Additions of instruments was $3.002 million against $14.389 million a year ago. Purchases of property, plant and equipment was $2.366 million against $3.307 million a year ago. Non-GAAP adjusted EBITDA was $14.321 million against $9.163 million a year ago. Non-GAAP adjusted free cash flow was $0.157 million against $3.886 million a year ago. Non-GAAP adjusted net loss was $3.028 million or $0.06 per basic and diluted share against $8.219 million or $0.17 per basic and diluted share a year ago. For the year, revenue was $344.953 million against $310.959 million a year ago. Operating loss was $21.422 million against $24.074 million a year ago. Loss before income taxes was $27.881 million against $34.077 million a year ago. Consolidated net loss was $29.471 million or $0.60 per basic and diluted share against $36.426 million or $0.79 per basic and diluted share a year ago. Net cash provided by operating activities was $1.008 million against $24.982 million a year ago. Additions of instruments was $21.751 million against $23.805 million a year ago. Purchases of property, plant and equipment was $10.494 million against $10.825 million a year ago. Non-GAAP adjusted EBITDA was $33.958 million against $30.438 million a year ago. Non-GAAP adjusted free cash flow was $31.237 million against $9.648 million a year ago. Non-GAAP adjusted net loss was $24.904 million or $0.51 per basic and diluted share against $27.236 million or $0.59 per basic and diluted share a year ago. For the year ended December 27, 2015, The company expects full year revenue to be in the range of $359 million to $371 million, representing constant currency growth between 4.1% to 7.6% compared to 2014 revenue. Reported revenue is projected to be in the range of $338.3 to $349.6 million, representing a change of negative 1.9% to 1.3% over last year. Earnings per share to be negative in the range of $0.65 to $0.38 per share. Adjusted EBITDA to be in the range of $35 to $39 million, or 10.3% to 11.2% of reported revenue. Operating loss to be in the range of $22.8 to $11.8 million. Free cash flow to be in the range of negative $5 million to negative $15 million. Along with this, capital expenditures to be similar to 2014 in the range of $30 million to $35 million during 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRNX:US $25.20 USD 0.00

TRNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alphatec Holdings Inc $1.35 USD -0.07
Exactech Inc $21.58 USD -0.37
Orthofix International NV $33.20 USD -0.14
RTI Surgical Inc $6.26 USD +0.32
Wright Medical Group Inc $24.92 USD +0.01
View Industry Companies
 

Industry Analysis

TRNX

Industry Average

Valuation TRNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TORNIER NV, please visit www.tornier.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.